Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-004448-12
    Sponsor's Protocol Code Number:ARQ087-301
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-02-02
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-004448-12
    A.3Full title of the trial
    A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
    Studio pilota di ARQ in soggetti con colangiocarcinoma intraepatico inoperabile o avanzato positivo alla fusione del gene FGFR2
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to investigate the effects of the drug ARQ 087 in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholanciocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion.
    Uno studio per valutare gli effetti del farmaco ARQ 087 in pazienti che hanno un tipo di tumore al dotto biliare molto esteso o che non possono essere operati, chiamato Colangiocarcinoma Intraepatico. I pazienti sono positivi alla fusione del gene FGFR2
    A.3.2Name or abbreviated title of the trial where available
    ARQ 087 in subjects with FGFR2 gene fusion in inoperable or advanced intrahepatic cholangiocarcinoma
    ARQ 087 in soggetti con colangiocarcinoma intraepatico inoperabile o avanzato e fusione del gene FGF
    A.4.1Sponsor's protocol code numberARQ087-301
    A.5.1ISRCTN (International Standard Randomised Controlled Trial) NumberISRCTN12345678
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT12345678
    A.5.3WHO Universal Trial Reference Number (UTRN)U1234-1234-1234
    A.5.4Other Identifiers
    Name:ARQ 087Number:ARQ 087
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorARQULE INC
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportArQule, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationArQule, Inc.
    B.5.2Functional name of contact pointManager, RA/QA
    B.5.3 Address:
    B.5.3.1Street AddressOne Wall Street
    B.5.3.2Town/ cityBurlington
    B.5.3.3Post code01803
    B.5.3.4CountryUnited States
    B.5.4Telephone number+17819940393
    B.5.5Fax number+17813766019
    B.5.6E-mailalusis@arqule.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/245/15
    D.3 Description of the IMP
    D.3.1Product nameARQ 087
    D.3.2Product code ARQ 087
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 1821329-75-2
    D.3.9.2Current sponsor codeARQ 087
    D.3.9.3Other descriptive nameARQ 087•2HCl
    D.3.9.4EV Substance CodeSUB183751
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Inoperable or advanced FGFR2 gene fusion positive intrahepatic cholangiocarcinoma
    Colangiocarcinoma intraepatico inoperabile o avanzato positivo alla fusione del gene FGFR2
    E.1.1.1Medical condition in easily understood language
    A type of bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion
    Un tipo di tumore al dotto biliare che non si può operare o molto esteso, in pazienti positivi per la fusione del gene FGFR2
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10073078
    E.1.2Term Intrahepatic cholangiocarcinoma recurrent
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10073077
    E.1.2Term Intrahepatic cholangiocarcinoma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the anti-cancer activity by Objective Response Rate (ORR)
    by central radiology review as per Response Evaluation Criteria in Solid
    Tumors (RECIST) version 1.1 in subjects with inoperable or advanced
    iCCA whose tumors harbor FGFR2 gene fusions (by FISH performed by a central laboratory) and who received at least one prior regimen of systemic therapy
    Valutare l'attività antitumorale misurata con tasso di risposta obiettiva (ORR) tramite revisione radiologica centralizzata ai sensi dei criteri di valutazione della risposta nei tumori solidi (RECIST) versione 1.1 in soggetti con colangiocarcinoma intraepatico inoperabile o avanzato con tumori caratterizzati da fusioni del gene FGFR2 (tramite FISH eseguita da un laboratorio centrale) e che hanno ricevuto almeno un regime precedente di terapia sistemica
    E.2.2Secondary objectives of the trial
    • To evaluate progression free survival (PFS) by central radiology review and overall survival (OS)
    • To evaluate duration of response (DoR) by central radiology review
    • To evaluate the safety profile (toxicities) of ARQ 087 in this subject population
    • Valutare la sopravvivenza libera da progressione (PFS) tramite revisione radiologica centralizzata e la sopravvivenza complessiva (OS)
    • Valutare la durata della risposta (DoR) tramite revisione radiologica centralizzata
    • Valutare il profilo di sicurezza (tossicità) di ARQ 087 in tale popolazione di soggetti
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Tissue samples for genetic testing will be obtained from subjects who meet the following pre-screening eligibility criteria:
    1. Signed written informed consent to permit tissue analysis
    2. 18 years of age or older
    3. No medical history that is excluded per the study treatment eligibility criteria
    4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Appendix 2 of the protocol)
    5. Eligible for or receiving systemic therapy for inoperable or advanced iCCA
    6. Not currently eligible for curative local or surgical therapy
    To be enrolled in the study, once the FGFR2 gene fusion status is determined, each prospective subject must meet all of the following inclusion criteria:
    1. Signed written informed consent granted prior to initiation of any study-specific procedures
    2. 18 years of age or older
    3. Histologically or cytologically confirmed locally advanced, inoperable (where surgery is not indicated due to disease extension, co-morbidities, or other technical reasons), or metastatic iCCA or mixed histology tumors (combined hepatocellular-cholangiocarcinoma [cHCC-CCA])
    4. FGFR2 gene fusion status confirmed by NGS or FISH testing
    - Test positive by FISH by the central laboratory designated by the Sponsor
    - Have FGFR2 gene fusion documented by a local or central laboratory using standard protocols and approved by local IRB/IEC, Clinical Laboratory Improvement Amendments (CLIA), or other similar agency. If the FGFR2 gene fusion is identified by a laboratory other than the Sponsor’s central laboratory, then archival and/or recent tissue biopsy samples or a tissue block suitable for genetic testing must be available for confirmatory testing by FISH by the Sponsor’s central laboratory (Refer to Section 6.7 and the Laboratory Manual for tissue preparation requirements). If a subject has documentation from a local or central laboratory indicating that they test negative for FGFR2 gene fusion, that subject may not be enrolled in the study.
    5. Received at least one regimen of prior systemic therapy and then experienced documented radiographic progression or was not able to tolerate prior systemic therapy.
    - if the subject received at least 4 cycles of systemic therapy and no measurable tumor reduction compared to the previous scan is observed, such subject can be enrolled
    - if the subject received immunotherapy, the documented radiographic disease progression is required
    - if the subject experienced disease progression within 6 months of adjuvant therapy, such therapy should be considered as the line of treatment rather than adjuvant therapy
    6. Measurable disease by RECIST version 1.1 criteria
    7. ECOG performance status ≤ 1 (Appendix 2)
    8. Adequate organ functions as indicated by the following laboratory values (based on screening visit values from the central laboratory).
    - Hematological
    ◦ Hemoglobin (Hgb) ≥ 9.0 g/dL
    ◦ Absolute neutrophil count (ANC) ≥ 1.5 x 10*9/L
    ◦ Platelet count ≥ 75 x 10*9/L
    ◦ International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ≤ 3 for subjects receiving anticoagulant therapy such as Coumadin or heparin
    - Hepatic
    ◦ Total bilirubin ≤ 2 x ULN
    ◦ Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 ULN (≤ 5 x ULN for subjects with liver metastases)
    ◦ Albumin ≥ 2.8 g/dL
    - Renal
    ◦ Serum creatinine ≤ 1.5 x ULN
    ◦ Creatinine clearance of ≥ 60 mL/min as estimated by the Cockcroft-Gault equation
    9. Male or female subjects of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after the last dose of ARQ 087
    Saranno prelevati campioni di tessuto per i test genetici dai soggetti che soddisfano i seguenti criteri di idoneità pre-screening:
    1. Consenso informato scritto per permettere l'analisi del tessuto
    2. Minimo 18 anni di età
    3. Nessuna anamnesi medica che venga esclusa dai criteri di idoneità al trattamento
    4. Stato prestazionale ≤ 1 dell'Eastern Cooperative Oncology Group (ECOG) (Appendice 2)
    5. Idoneità a o ricevimento di terapia sistemica per iCCA inoperabile o avanzato
    6. Non idoneità attuale a terapia curativa locale o chirurgica
    Per l'arruolamento nello studio, una volta determinato lo stato di fusione del gene FGFR2, ogni potenziale soggetto deve soddisfare tutti i criteri di inclusione:
    1. Consenso informato scritto firmato rilasciato prima dell'inizio di qualsiasi procedura specifica dello studio
    2. Minimo 18 anni di età
    3. iCCA localmente avanzato, inoperabile (in cui l'intervento non è indicato per via dell'estensione della malattia, di comorbilità o di altri motivi tecnici) o metastatico istologicamente o citologicamente confermato o tumori istologici misti (colangiocarcinoma epatocellulare combinato [cHCC-CCA])
    4. Fusione del gene FGFR2 confermata da test NGS o FISH
    - Test positivo eseguito tramite FISH dal laboratorio centrale designato dallo Sponsor
    - Fusione del gene FGFR2 documentata da un laboratorio locale o centrale utilizzando protocolli standard e approvati dall'IRB/IEC locale, dagli emendamenti per il miglioramento dei laboratori clinici (Clinical Laboratory Improvement Amendments, CLIA) o da un'agenzia simile. Se la fusione del gene FGFR2 viene identificata da un laboratorio diverso dal laboratorio centrale dello Sponsor, devono essere disponibili campioni di tessuto bioptico di archivio e/o recenti per i test di conferma tramite FISH da parte del laboratorio centrale dello Sponsor (consultare la Sezione 6.7 e il Manuale di laboratorio per i requisiti di preparazione del tessuto). Se un soggetto presenta la documentazione di un laboratorio locale o centrale che indica un risultato negativo del test per la fusione del gene FGFR2, tale soggetto non può essere arruolato nello studio.
    5. Ricevimento di almeno un regime di terapia sistemica precedente e quindi manifestarsi di progressione radiografica documentata o impossibilità a tollerare la terapia sistemica precedente.
    - se il soggetto ha ricevuto almeno 4 cicli di terapia sistemica e non viene osservata nessuna riduzione misurabile del tumore rispetto alla scansione precedente, tale soggetto può essere arruolato
    - se il soggetto ha ricevuto immunoterapia, è richiesta la progressione radiografica documentata della malattia
    - se il soggetto ha subito progressione della malattia entro 6 mesi di terapia adiuvante, tale terapia dovrebbe essere considerata come linea di trattamento e non come terapia adiuvante
    6. Malattia misurabile in base ai criteri RECIST versione 1.1
    7. Stato prestazionale ECOG ≤ 1 (appendice 2 del protocollo)
    8. Funzionalità epatica adeguata indicata dai seguenti valori di laboratorio (sulla base dei valori della visita di screening forniti dal laboratorio centrale):
    - Ematologici
    ◦ Emoglobina (Hgb) ≥ 9,0 g/dl
    ◦ Conta assoluta dei neutrofili (ANC) ≥ 1,5 x 10*9/l
    ◦ Conta piastrinica ≥ 75 x 10*9/l
    ◦ Rapporto normalizzato internazionale (INR) 0,8 volte i limiti superiori del normale (ULN) o ≤ 3 per i soggetti che ricevono terapia anticoagulante come Coumadin o eparina
    - Epatici
    ◦ Bilirubina totale ≤ 2 x LSN
    ◦ Aspartato aminotransferasi (AST) e alanina aminotransferasi (ALT) ≤ 3 ULN (≤ 5 x ULN per i soggetti con metastasi epatiche)
    ◦ Albumina ≥ 2,8 g/dl
    - Renali
    ◦ Creatinina sierica ≤ 1,5 x ULN
    ◦ Clearance della creatinina di ≥ 60 ml/min stimata tramite l'equazione di Cockcroft-Gault
    9. I soggetti maschili o femminili in età fertile devono accettare di impiegare misure contraccettive a doppia barriera, contraccezione orale o astensione dai rapporti sessuali durante lo studio e per 90 giorni dopo l'ultima dose di ARQ 087
    E.4Principal exclusion criteria
    1. Systemic anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ARQ 087
    2. Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of ARQ 087
    3. Previous treatment with any FGFR inhibitor (e.g., ponatinib, dovitinib, nintedanib, AZD4547, NVP-BGJ398, LY2784455, BAY1163877)
    - Subjects who received less than four weeks of therapy and were unable to continue therapy due to toxicity will be allowed to participate
    4. Unable or unwilling to swallow the complete daily dose of ARQ 087 capsules
    5. Clinically unstable central nervous system (CNS) metastases (to be eligible, subjects must have stable disease ≥ 3 months, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and/or have CNS metastases well controlled by low-dose steroids, anti-epileptics, or other symptom-relieving medications)
    6. Current evidence of corneal or retinal disorder, including but not limited to bullous/band keratopathy, keratoconjunctivitis, corneal abrasion, inflammation/ulceration, confirmed by ophthalmologic examination
    7. Concurrent uncontrolled or active hepatobiliary disorders, untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, biloma or abscess (to be eligible, the subjects have to be treated and disorders/complications should be resolved within 2 weeks prior to the first dose of ARQ 087)
    8. History of significant cardiac disorders:
    - Myocardial infarction (MI) or congestive heart failure defined as Class II to IV per the New York Heart Association (NYHA) classification within 6 months of the first dose of ARQ 087 (MI that occurred > 6 months prior to the first dose of ARQ 087 will be permitted)
    - QTcF > 500 msec (males or females)
    9. Significant gastrointestinal disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 087 (e.g., Crohn’s disease, ulcerative colitis, extensive gastric resection)
    10. Previous malignancy within 2 years of the first dose of ARQ 087, except curatively treated or low grade malignancies such as non-melanoma skin cancer, carcinoma in-situ of the breast, cervix, and superficial bladder tumors
    11. Concurrent uncontrolled illness not related to cancer, including but not limited to:
    - Psychiatric illness/substance abuse/social situation that would limit compliance with study requirements
    - Known uncontrolled human immunodeficiency virus (HIV) infection
    12. Blood or albumin transfusion within 5 days of the blood draw being used to confirm eligibility
    13. Pregnant or breast feeding
    1. Terapia antitumorale sistemica, come chemioterapia, immunoterapia, terapia ormonale o mirata o agenti sperimentali entro quattro settimane dalla prima dose di ARQ 087
    2. Intervento chirurgico importante, terapia locoregionale o radioterapia entro quattro settimane dalla prima dose di ARQ 087
    3. Trattamento precedente con qualsiasi inibitore dell'EGFR (ad esempio, ponatinib, dovitinib, nintedanib, AZD4547, NVP-BGJ398, LY2784455, BAY1163877)
    - I soggetti che hanno ricevuto meno di quattro settimane di terapia e non hanno potuto continuare la terapia a causa di tossicità potranno partecipare
    4. Impossibilità o mancata disponibilità a deglutire la dose giornaliera completa di capsule di ARQ 087
    5. Metastasi al sistema nervoso centrale (NSC) clinicamente instabili (per essere idonei, i soggetti devono avere malattia stabile ≥ 3 mesi, confermata da risonanza magnetica (RM) o tomografia computerizzata (TAC) e/o devono presentare metastasi all'NSC ben controllate da steroidi a basso dosaggio, antiepilettici o altri farmaci per alleviare i sintomi)
    6. Evidenze attuali di disturbo corneale o retinico, tra cui, a titolo esemplificativo ma non esaustivo, cheratopatia bollosa/a bandelletta, cheratocongiuntivite, abrasione corneale, infiammazione/ulcera, confermate da esame oftalmico
    7. Disturbi epatobiliari incontrollati o attivi concomitanti, non trattati o soggetti a complicanze dopo procedure laparoscopiche o inserzione di stent, tra cui, a titolo esemplificativo ma non esaustivo, colangite attiva, biloma o ascesso (per essere idonei, i soggetti devono essere stati trattati e i disturbi/le complicanze devono essersi risolti entro 2 settimane prima della prima dose di ARQ 087)
    8. Anamnesi di disturbi cardiaci significativi:
    - Infarto del miocardio (MI) o insufficienza cardiaca congestizia definita come di Classe da II a IV in base alla classificazione della New York Heart Association (NYHA) entro 6 mesi dalla prima dose di ARQ 087 (sarà consentito un MI verificatosi > 6 mesi prima della prima dose di ARQ 087)
    - QTcF > 500 msec (maschi o femmine)
    9. Disturbo/i gastrointestinale/i significativo/i che, secondo il parere dello sperimentatore, potrebbe/potrebbero interferire con l'assorbimento, il metabolismo o l'escrezione di ARQ 087 (ad esempio, morbo di Crohn, colite ulcerativa, resezione gastrica estesa)
    10. Precedente neoplasia entro 2 anni dalla prima dose di ARQ 087, fatta eccezione per le neoplasie trattate con intento curativo o di basso grado come il carcinoma non melanomico, il carcinoma in-situ della mammella o della cervice o i tumori vescicali superficiali
    11. Malattia non controllata concomitante non correlata al cancro, tra cui, a scopo esemplificativo ma non esaustivo:
    - Malattia psichiatrica/abuso di sostanze/situazione sociale che limiterebbe la conformità ai requisiti dello studio
    - Infezione da virus dell’immunodeficienza umana (HIV) non controllata nota
    12. Trasfusione di sangue o albumina entro 5 giorni dal prelievo di sangue usato per confermare l'idoneità
    13. Gravidanza o allattamento al seno
    E.5 End points
    E.5.1Primary end point(s)
    ORR will be the proportion of subjects with confirmed complete responses and partial responses by central radiology review as per RECIST version 1.1
    L'ORR sarà la proporzione di soggetti con risposte complete e parziali confermate tramite revisione radiologica centralizzata in base a RECIST versione 1.1
    E.5.1.1Timepoint(s) of evaluation of this end point
    Tumor assessments (CT or MRI scan) of the chest, abdomen, and pelvis will be done at screening, once every 8 weeks (every 2 cycles) from the day of the first dose for the first 6 cycles (C3D1, C5D1, C7D1), and once every 12 weeks (every 3 cycles) thereafter (C10D1, C13D1, etc.). The End of Treatment scan will be done if the previous scan was not done within four weeks (28 days) prior to the End of Treatment visit or if the previous scan did not show radiographic disease progression.
    La valutazione del tumore (scansioni con TAC o risonanza magnetica) di torace, addome e pelvi viene effettuata allo screening, ogni 8 settimane (ogni 2 cicli) dal giorno della prima dose per i primi 6 cicli (C3D1, C5D1, C7D1), e successivamente ogni 12 settimane (ogni 3 cicli) (C10D1, C13D1, ecc.). La scansione alla fine del trattamento verrà fatta se la precedente scansione non è stata effettuata entro 4 settimane (28 giorni) prima della visita di fine trattamento o se la precedente scansione non ha confermato radiograficamente la progressione della malattia.
    E.5.2Secondary end point(s)
    • DoR will be calculated from the first date of documented tumor response to disease progression by central radiology review
    • PFS will be calculated from the first date of receiving study drug until radiographic disease progression by central radiology review or death
    • OS will be calculated from the first date of receiving study drug until death
    • La DoR sarà calcolata dalla prima data della risposta tumorale documentata alla progressione della malattia tramite revisione radiologica centralizzata
    • La PFS sarà calcolata dalla prima data di ricevimento del farmaco in studio fino alla progressione radiografica della malattia tramite revisione radiologica centralizzata o al decesso
    • La OS sarà calcolata dalla prima data di ricevimento del farmaco in studio fino al decesso
    E.5.2.1Timepoint(s) of evaluation of this end point
    DoR and PFS: Tumor assessments (CT or MRI scan) of the chest, abdomen, and pelvis will be done every 8 weeks (every 2 cycles) from the day of the first dose for the first 6 cycles (C3D1, C5D1, C7D1) and once every 12 weeks (every 3 cycles) thereafter (C10D1, C13D1, etc.). The End of Treatment scan will be done if the previous scan was not done within four weeks (28 days) prior to the End of Treatment visit or if the previous scan did not show radiographic disease progression.

    OS: from the first date of receiving study drug until death.
    DoR e PFS: La valutazione del tumore (scansioni con TAC o risonanza magnetica) di torace, addome e pelvi viene effettuata ogni 8 settimane (ogni 2 cicli) dal giorno della prima dose per i primi 6 cicli (C3D1, C5D1, C7D1) e una volta ogni 12 settimane (ogni 3 cicli) successivamente (C10D1, C13D1, ecc.). La scansione alla fine del trattamento verrà fatta se la precedente scansione non è stata effettuata entro 4 settimane (28 giorni) prima della visita di fine trattamento o se la precedente scansione non ha confermato radiograficamente la progressione della malattia.
    OS: dalla prima data di somministrazione del farmaco fino alla morte
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Information not present in EudraCT
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over Information not present in EudraCT
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA6
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Canada
    France
    Germany
    Italy
    Netherlands
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days30
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days30
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 1
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 65
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 35
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 50
    F.4.2.2In the whole clinical trial 100
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard medical care, other experimental treatment or other clinical research studies.
    Assistenza medica standard, altri trattamenti sperimentali o altri studi di ricerca clinica.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-12-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-11-22
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:19:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA